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Neuroinflammation is often associated with blood-brain-barrier dysfunction, which con-
tributes to neurological tissue damage. Here, we reveal the pathophysiology of Susac syn-
drome (SuS), an enigmatic neuroinflammatory disease with central nervous system (CNS)
endotheliopathy. By investigating immune cells from the blood, cerebrospinal fluid, and CNS
of SuS patients, we demonstrate oligoclonal expansion of terminally differentiated activated
cytotoxic CD8+ T cells (CTLs). Neuropathological data derived from both SuS patients and a
newly-developed transgenic mouse model recapitulating the disease indicate that CTLs
adhere to CNS microvessels in distinct areas and polarize granzyme B, which most likely
results in the observed endothelial cell injury and microhemorrhages. Blocking T-cell adhe-
sion by anti-α4 integrin-intervention ameliorates the disease in the preclinical model. Simi-
larly, disease severity decreases in four SuS patients treated with natalizumab along with
other therapy. Our study identifies CD8+ T-cell-mediated endotheliopathy as a key disease
mechanism in SuS and highlights therapeutic opportunities.
https://doi.org/10.1038/s41467-019-13593-5 OPEN
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Brain endothelial cells (ECs) are major elements of theblood–brain barrier (BBB), which contribute to centralnervous system (CNS) homeostasis, maintenance, and
neuronal function by restricting the entry of circulating leuko-
cytes and blood-derived molecules into the CNS1,2. Compro-
mised function of brain ECs resulting in impaired integrity of the
BBB is an early hallmark of various neurological diseases. These
include not only autoimmune inflammatory disorders, such as
multiple sclerosis (MS), neuromyelitis optica, and Rasmussen
encephalitis, but also infections such as cerebral malaria and
arbovirus-related encephalitis, as well as cerebrovascular diseases,
such as ischemic stroke3. Upon their active entry into the CNS,
leukocytes can contribute to lesion development4,5. Although
several mechanisms targeting brain ECs and resulting in BBB
dysfunction have been described, the impact and function of
lymphocytes during these processes are still poorly understood2.
To gain further insights into the underlying mechanisms
resulting in BBB dysfunction caused by lymphocytes, we inves-
tigate the pathophysiology of Susac syndrome (SuS)6, which is
considered an inflammatory endotheliopathy. SuS is a rare neu-
rological disease mainly affecting young adults between 20 and
40 years, with a female-to-male ratio of 3.5/17. Since its first
description in 19798, approximately 400 cases have been reported
worldwide7. SuS patients present with a clinical triad of ence-
phalopathy, visual disturbances caused by branch retinal artery
occlusions, and sensorineural hearing deficits7. Histopathology
studies suggest that the clinical manifestations are caused by focal
microangiopathy affecting the small-to-medium-size vessels of
the brain, retina, and inner ear9,10.
The pathogenesis of SuS remains enigmatic. An (auto)immune
process leading to the disruption and occlusion of microvessels in
the affected organs has been postulated11. Elevated serum levels
of anti-EC antibodies (AECA) are found in approximately 25% of
SuS patients12,13, suggestive of a pathogenic scenario involving an
antibody-mediated attack against ECs. However, this hypothesis
has been challenged, since AECA are only detected in a subset of
patients and are not associated with disease severity12. Further-
more, few CD20+ B cells and no plasma cells are present in CNS
biopsies of SuS patients9. However, the clear response of SuS to
immunosuppressive and immunomodulatory drugs13–15 strongly
supports the hypothesis that SuS is immune mediated and
scant perivascular T lymphocytes have been demonstrated
histopathologically9.
Here, by combining in-depth immune profiling and pheno-
typing of blood and cerebrospinal fluid (CSF) samples with a
pathological study of brain tissue from patients with SuS6 or its
differential diagnosis MS, we reveal distinct underlying mechan-
isms in these two chronic neuroinflammatory diseases. Further-
more, we mimic the scenario of an antigen-specific CD8+ T cell
attack against CNS endothelium in a mouse model. Taken
together, we demonstrate that cytotoxic CD8+ T cells (CTLs) can
cause vascular CNS injury and identify CTL-mediated endothe-
liopathy as a targetable mechanism in SuS.
Results
Intrathecal and circulating CD8+ T cells are altered in SuS. In
accordance with previous case reports9,10,16, immunohistochem-
ical characterization of brain tissue specimen from seven SuS
patients revealed the presence of immune cells (Fig. 1a). Quan-
tification showed that the majority of CNS infiltrates in SuS were
composed of CD3+ T cells, mainly consisting of CD8+ T cells
ranging from 56% to 89% of T cells. Contrasting with the density
of CD8+ T cells (mean density 14 CD8+ T cells mm−2; ranging
from 2.3 to 73.2 CD8+ T cells mm−2), few CD20+ B cells
were detected in brain parenchyma (mean density 0.4 CD20+ B
cells mm−2), and no antibody-producing CD138+ plasma cells
were observed.
We further assessed SuS-specific changes in the intrathecal
compartment by multi-parameter flow cytometry CSF analysis
(Fig. 1b, Supplementary Fig. 1a, Supplementary Table 1). Immune
profiles of patients with SuS were compared to MS patients, one
of the major differential diagnosis of SuS. Furthermore, patients
with neurological manifestations who could not be ascribed to
any medical condition (somatoform disorders) and in the absence
of an inflammatory CSF served as a non-inflammatory control
group. Although 36% of the SuS patients displayed a disruption of
the blood–CSF barrier, CSF cell counts in SuS patients remained
within normal range (2.4 ± 4.6 cells µl−1 CSF, Supplementary
Table 2). In contrast, MS patients are usually characterized
by mild pleocytosis (6.8 ± 8.8 cells µl−1 CSF) as previously
reported17–19, resulting in a significant increase of all lymphocyte
subsets studied, including T and B cells (Supplementary Fig. 2a).
Although the proportion of CD19+ B cells was slightly increased
in the CSF of SuS patients, no antibody-producing CD138+
plasma cells were found; the latter being a typical feature of MS
CSF (Fig. 1b). Accordingly, intrathecal immunoglobulin (Ig)
synthesis and presence of oligoclonal bands were present in the
majority of MS cases but absent in SuS (Supplementary Table 2).
Notably, owing to both increased proportion of CD8+ T cells and
decreased proportion of CD4+ T cells, the intrathecal CD4/CD8
ratio was decreased in SuS patients compared to both non-
inflammatory controls and MS patients (Fig. 1b). The proportion
of activated HLA-DR-expressing CD8+ T cells was significantly
increased both in the CSF and in the peripheral blood of SuS
patients, a feature also not shared by MS patients. Moreover,
absolute numbers of HLA-DR+ CD8+ T cells were also increased
in the CSF of SuS patients (Supplementary Fig. 2a). Of note,
no differences in the peripheral as well as intrathecal T cell
compartment were detected between treatment-naive SuS
patients and those on corticosteroids (Supplementary Fig. 2b).
The frequency of circulating CD45RA+CD62L− terminally
differentiated effector memory CD8+ T cells (CD8+ TEMRA),
but not CD4+ TEMRA cells, was significantly increased in SuS
patients (Fig. 1c, Supplementary Fig. 1b), suggesting that a strong
and prolonged antigenic stimulus had triggered CD8+ T cell
differentiation20. This feature was characteristic for SuS and
unlike healthy controls showed no positive correlation with age
(Supplementary Fig. 3a). In SuS, a trend for greater proportion of
CD8+ TEMRA cells was detected close to disease onset, suggesting
that these cells may contribute to disease development (Supple-
mentary Fig. 3b).
CD8+ T cells in SuS contain disease-specific expanded clones.
To explore whether the observed activation and differentiation of
CD8+ T cells was antigen driven, the T cell receptor (TCR)
repertoire was first analyzed by Vβ complementarity-determining
region 3 (Vβ-CDR3) spectratyping21 (Fig. 2a). Compared to
healthy individuals, SuS patients exhibited a decreased complexity
score of CD8+ T cells as well as an increase in the oligoclonal
profile of the Vβ-CDR3 spectratypes, indicating a significant
clonal expansion in the CD8+ T cell compartment. In contrast,
despite a more skewed phenotype, no oligoclonal expansion was
detectable with this technique in the peripheral CD4+ T cell
repertoire of SuS patients.
Since spectratyping provides little quantitative detail about
individual TCR clonotypes and sequence identity, we performed
next-generation deep sequencing of the Vβ-CDR3 region22,23 as a
complementary method to study the TCR repertoire. This
technology enables determination of clonal frequencies conco-
mitant with sequence identification24. Clonal expansions in
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CD8+ T cells were confirmed (Fig. 2b, c). Notably, clonality
significantly correlated with proportions of CD8+ TEMRA cells
(Supplementary Fig. 4a) and accordingly highest clonality was
observed in the CD8+ TEMRA repertoire (Fig. 2b, c), both in
treatment-naive and corticosteroid-treated patients (Supplemen-
tary Fig. 4b). Moreover, while the overall CD8+ T cell repertoire
was clonally diverse, the CD8+ TEMRA repertoire was clearly
restricted. Again, no clonal expansion was detected within the
CD4+ T cell compartment (Supplementary Fig. 4c). Interestingly,
clinically active SuS patients showed significantly higher clonal
expansion levels of CD8+ T cells than patients in remission
(Fig. 2d), further supporting the relationship to pathogenesis.
These disease-related changes in clonality were not observed in
the CD4+ T cell compartment (Supplementary Fig. 4d).
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T cell responses to a given antigen are likely to involve clones
that are private, i.e., only found in one individual, as well as
public, i.e., shared by different individuals25. Especially in
individuals that share at least some HLA background public
clonal expansions might be directed against similar antigens. To
further investigate the pathogenic relevance of clonally expanded
CD8+ T cells in SuS, we analyzed the 100 most prevalent clones
in each patient and control. We identified 16 and 5 SuS-specific
public clones in the total CD8+ T cell and CD8+ TEMRA
repertoire, respectively, which were shared by at least two SuS
patients, but absent in healthy individuals and MS patients
(Table 1). These disease-specific public clones were not linked to
other published disease-related clones, including known virus-
specific clones26–29.
Although the presence of public clonal T cell responses may
suggest a shared specific pathogenic relevance25, further analysis
revealed that the ten clones with the highest copy number, which
represented 20% of the total CD8+ T cells and 55% of the CD8+
TEMRA repertoire (Fig. 2e), were private and only found in
individual SuS patients (Fig. 2f, Supplementary Table 3). Of note,
SuS-specific private clones within the CD8+ TEMRA repertoire
exhibited unique characteristics with increased CDR3 length
(Supplementary Fig. 4e, f) and higher numbers of nucleotide
insertions in the N1 and N2 regions of the CDR3 (Supplementary
Fig. 4g) when compared to public clones. In accordance with
previous reports, CDR3 length is a prominent feature of private
clones that is based on stochastic probability of a TCR
recombination being more likely for a short CDR3 sequence30.
Although the number of individuals was relatively small, SuS
patients included in this analysis shared a similar HLA allele,
except for one patient, who was homozygous for HLA-C*04
(Supplementary Table 4). Twelve out of 14 subjects expressed
HLA-C*07. Moreover, 5 out of 14 subjects expressed HLA-C*06,
which has a peptide-binding motif very similar to that of HLA-
C*0731,32.
Taken together, analysis of the peripheral TCR repertoire in
SuS patients demonstrates that SuS is not only characterized by a
strong drive for differentiation of CD8+ T cells into CD8+ TEMRA
cells but also by significant clonal expansion, particularly within
CD8+ TEMRA cells (but not in CD4+ T cell compartment)—
consistent with the hypothesis of an antigen-specific process
underlying the disease pathogenesis.
CD8+ T cells exhibit increased cytolytic potential in SuS. Given
their clonal expansion and altered differentiation, we further
characterized the function of CD8+ T cells from SuS patients.
Freshly isolated peripheral CD8+ T cells from SuS patients
expressed the cytotoxic molecules granzyme B (GrB) and perforin
(Fig. 3a, Supplementary Fig. 1c) at higher levels than those of
healthy individuals and MS patients, in line with increased pro-
portions of CD57+ bona fide CTLs in SuS (Supplementary
Fig. 5a). Consistent with the immunophenotyping and repertoire
data, the highest increases of GrB and perforin were observed in
the CD8+ TEMRA cell subset (Supplementary Fig. 1c, Supple-
mentary Fig. 5b), a phenomenon not explained by age-related
changes (Supplementary Fig. 3a). Moreover, freshly isolated
CD8+ T cells of SuS patients released more cytotoxic granules
upon TCR triggering in a re-directed lysis assay than those of
healthy individuals and MS patients, suggesting a higher pro-
pensity for effector reactivity in SuS patients (Fig. 3b).
States of chronic inflammation are often characterized by
dysfunctional regulatory cell populations33,34 and/or resistance to
immune regulation, e.g., by regulatory T cells (Treg)35,36. There-
fore, we assessed immune regulatory capacities in SuS. While
frequencies (Supplementary Fig. 6a) and suppressive capacity
(Fig. 3c) of Treg remained unaffected in SuS, CD8+ T cells derived
from SuS patients exhibited not only a high cytotoxic activity
(Fig. 3a, b) but also resisted suppression by Treg (Fig. 3c). Of note,
resistance to suppression by Treg was not observed in the CD4 T
cell compartment (Supplementary Fig. 6b).
CTLs accumulate at damaged CNS microvessels in SuS.
Quantitative and qualitative changes in circulating GrB- and
perforin-expressing CD8+ T cells suggested that CTLs could be
responsible for SuS-specific endotheliopathy. We therefore
investigated their contribution by immunohistochemistry of brain
lesions from seven SuS patients (Supplementary Table 1, Table 2)
We found that CD8+ T cells significantly accumulated in the
lumen and the perivascular space of brain microvessels of SuS
patients (Fig. 4a). Unlike in encephalitis patients37, CTLs did not
penetrate deeply into the parenchyma. The proportion of CD8+
T cells adhering to ECs was significantly increased in SuS patients
compared to MS patients (Fig. 4m). Furthermore, GrB-expressing
cells (Fig. 4b) were found in direct apposition to major histo-
compatibility complex (MHC) class-I-expressing brain ECs
(Fig. 4c). Adherent CD8+ T cells showed polarized GrB-
containing cytotoxic granules indicating initiation of the cytoly-
tic cascade (Fig. 4d, e). Polarization of cytotoxic granules in CD8+
T cells was associated with apoptosis of ECs, as indicated
by nuclear condensation (Fig. 4f, g) and TUNEL (terminal
deoxynucleotidyl transferase-mediated dUTP-fluorescein nick
end labeling) staining (Fig. 4h). Notably, the proportion of
apoptotic EC was clearly increased in SuS compared to MS
patients and non-inflammatory controls (Fig. 4n). Endothelial
loss was associated with microhemorrhages (Fig. 4e, g) and
leakage of the BBB as indicated by perivascular iron deposition
(Fig. 4i). Staining for C9 neo showed the absence of complement
deposition on ECs, suggesting that antibody-mediated comple-
ment activation does not play a role in EC degeneration (Table 2).
In addition, small ischemic lesions, as indicated by degeneration
of cerebellar granule cells, focal loss of astrocytes, myelin, and
axonal damage, were present in three of the patients (Fig. 4j–l).
Together these data strongly support the hypothesis that an
expanded and activated CTL-mediated endotheliopathy is a key
Fig. 1 Accumulation of activated CD8+ T cells in SuS. a Brain lesion from a patient with SuS stained for T cell markers CD3, CD8, and CD4, B cell marker
CD20, and the plasma cell marker CD138. Bars: 50 µm. Most T cells belong to the CD8+ T cell subset; light brown cells are most likely microglia cells;
B cells are rare (arrowhead). One B cell is enlarged in the insert. CD138+ plasma cells are absent from this and other lesions. The insert of the
CD138 staining shows plasma cells from a positive control (Rasmussen encephalitis). b Graphs representing proportions of CD19+ B cells (top left),
CD138+ plasma cells (top right) among lymphocytes and CD8+ T cells (middle left), CD4+ T cells (middle right), HLA-DR+CD8+ T cells (bottom left),
and HLA-DR+CD4+ T cells (bottom right) among CD3+ T cells in the peripheral blood (PB, closed symbols; SoD= 76; SuS= 32; MS= 227) and
cerebrospinal fluid (CSF, open symbols; SoD= 76; SuS= 14; MS= 227) of somatoform disorders (SoD, blue circles), SuS (cayenne squares), and MS
patients (red triangles up). c Quantification of naive, central memory (CM), effector memory (EM), and effector memory expressing CD45RA (EMRA)
CD8+ (left) and CD4+ (right) T cell subsets in the peripheral blood of healhy donors (HD; n= 20, closed blue circles), SuS (n= 20, closed cayenne
squares), and MS patients (n= 10, closed red triangles up). Statistical analysis was performed using Kruskal–Wallis test with Dunn’s post-test. Error bars
indicate the mean ± s.d.; p values: *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. Source data are provided as a Source Data file.
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pathogenic feature associated with or even causative of SuS
pathology.
EC-HA+ mice as a model for CTL-mediated endotheliopathy.
Based on the proposed antigen-driven and brain-endothelium
directed pathogenesis in SuS, we developed a mouse model
mimicking those features to directly test causal relationships. To
this end, we generated (Slco1c1-CreERT2 × Rosa26-Stop-HA)F1
mice, referred to as EC-HA+, (Supplementary Fig. 7a) that
express the influenza virus hemagglutinin (HA), as an endothelial
neo-antigen. Owing to the promoter used in this model, antigen
expression was found in ECs of the brain and retina38–40 as well
as inner ear41,42—the target organs in SuS but not in other tested
organs (Supplementary Fig. 7b). We have first assessed whether
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EC-HA+ mice generate any immune reaction to tamoxifen-
induced HA neoantigen. Therefore, prior to any CTL transfer, the
CNS of tamoxifen-treated mice was analyzed by flow cytometry
(five EC-HA+ and five EC-HA− mice) and brain histology (three
additional mice per group). No increased number of T cells and
no T cell infiltration in different parts of the CNS (cortex, hip-
pocampus, cerebellum, spinal cord, choroid plexus) were
observed in EC-HA+ animals. This indicates that the mere
expression of a neoantigen by brain ECs is not sufficient for
autoimmunity development. Adoptive transfer of activated HA-
specific CTLs (Supplementary Fig. 8a, b) in EC-HA+ or EC-HA−
mice resulted in CD3+ T cell infiltration in the retina, inner ear,
and brain of EC-HA+ but not in that of EC-HA− mice (Fig. 5a,
representative sections and quantification), indicating that organ-
specific antigen expression in ECs is responsible for T cell infil-
tration into the respective organs. Within the brain of EC-HA+
mice distinct regions including the corpus callosum, hippo-
campus, cerebellum, and cortex were infiltrated in a time-
dependent manner (Supplementary Fig. 8c). The vast majority of
CNS-infiltrating T cells consisted of the adoptively transferred
HA-specific CD45.1+ CD8+ T cells, whereas fewer endogenous
CD45.1- CD4+ and CD8+ T cells were detected in the brain
parenchyma (Supplementary Fig. 8a, d). CNS-infiltrating
CD45.1+ CTLs of EC-HA+ mice exhibited CD107a surface
exposure indicating cytotoxic activity (Fig. 5b). Furthermore, they
also expressed pro-inflammatory cytokines including interferon
(IFN)-γ and tumor necrosis factor (TNF)-α (Supplementary
Fig. 8e). Adoptive transfer of antigen-specific CTLs not only
resulted in T cell infiltrates in the brain, cerebellum, retina, and
inner ear of EC-HA+ mice but also led to significant weight loss
and diminished motor performance when compared to EC-HA−
mice (Fig. 5c). Neither clinical manifestations nor T cell infil-
tration was observed in EC-HA+ mice upon transfer of naive
HA-specific CD8+ T cells (Supplementary Fig. 8d).
These data demonstrate that adoptively transferred antigen-
specific CTLs are capable of inducing a neuroinflammatory
disease in mice expressing the respective antigen in brain ECs as
well as retina and inner ear, thus recapitulating major
pathological features of SuS.
CTL-mediated endotheliopathy results in a SuS-like pathology.
We next investigated the impact of antigen-specific CTLs on the
microvessels of EC-HA+ mice (Table 2). Following HA-specific
CTL transfer, CTLs accumulated in CNS microvessels (Fig. 6a) as
observed in SuS patients (Fig. 4a). Brain ECs from EC-HA+ mice
expressed MHC class-I molecules (Fig. 6b), permitting cognate
interaction with HA-specific CD8+ T cells. GrB-expressing CD8+
T cells accumulated in the vessel lumen and parenchyma in close
proximity to injured CD31+ ECs in EC-HA+ mice (Fig. 6c),
similar to our observations in SuS patients (Fig. 4d, e). Notably,
GrB was polarized toward ECs, suggesting focal release of GrB by
CTLs (Fig. 6d). HA expression in microvessels of the CNS
resulted in endothelial injury following transfer of HA-specific
CTLs, as indicated by apoptosis and loss of ECs (Fig. 6e–h,
quantified in Fig. 6i). Both deposition of IgG and perivascular
iron in the brain parenchyma further demonstrated breach of the
BBB in EC-HA+ mice as a result of adoptively transferred HA-
specific CTLs (Fig. 6j). Small ischemic lesions were also detected
in and above the corpus callosum 7 days after adoptive transfer of
HA-specific CTLs into EC-HA+ mice, as indicated by axonal
damage, focal loss of both oligodendrocytes and astrocytes, and
loss of endothelium (Fig. 6k). Notably, ECs from organs devoid of
HA expression such as liver, heart, lung, and kidney remained
intact (Supplementary Fig. 9).
In summary, our mouse model demonstrated that antigen-
specific CTLs induce apoptosis of antigen-expressing ECs,
resulting in microvascular damage to the brain cerebellum,
retina, and inner ear, reproducing the pathological features of
SuS. This also strongly supports the hypothesis that SuS is an
antigen-specific CTL-driven endotheliopathy.
α4 integrin blockade reduces disease in the mouse model. To
validate therapeutic targets using our preclinical model, EC-HA+
mice were treated with an anti-α4 integrin monoclonal antibody
(mAb) that impedes the interaction of VLA-4-expressing T cells
with vascular cell adhesion molecule 1 (VCAM-1) expressed on
ECs, thereby inhibiting adhesion of lymphocytes to the endo-
thelium43,44 and subsequent transmigration across the BBB19,45.
Antibody blockade of α4 integrin resulted in marked disease
amelioration, as indicated by stable weight and preserved motor
performance in EC-HA+ mice compared to their counterparts
treated with the corresponding isotype control (Fig. 7a).
Accordingly, the numbers of CNS-infiltrating endogenous T cells
as well as adoptively transferred HA-specific CTLs were sig-
nificantly decreased in anti-α4 integrin-treated mice (Fig. 7b).
These data thereby identify a therapeutic strategy to interfere with
the CTL-mediated endotheliopathy that drives the SuS-like phe-
notype in the mouse model.
Disease severity decreased in SuS patients under natalizumab.
Based on the assumption that immune cell trafficking into the
CNS and immune–endothelium interactions are crucial compo-
nents of SuS pathology, and following the strong support of this
hypothesis in our preclinical model, we used natalizumab, a
licensed humanized mAb approved for the therapy of active MS
and directed against the α4 integrin19,46. Natalizumab could
prevent binding of SuS-patient derived CD8+ T cells onto a
confluent human brain microvascular endothelial cell (HBMEC)
monolayer under shear flow conditions in vitro (Fig. 7c).
Fig. 2 Perturbations in the CD8+ TEMRA repertoire of SuS patients. a Complexity score (left) and CDR3 length distribution (right) of peripheral CD8+ and
CD4+ T cell repertoires of HD (closed blue circles, n= 11), SuS (closed cayenne squares, n= 7), and MS patients (closed red triangles up, n= 12) assessed
by TCR Vβ-CDR3 spectratyping. b Representative Manhattan plots showing TCR repertoires of CD8+ T cells from a HD (top left), a SuS patient (top right,
patient #10), a MS patient (bottom left), and SuS CD8+ TEMRA cells (bottom right, patient #10). The x-axis depicts all the Vβ genes, the z-axis the Jβ genes,
and the column heights represent the percentage reads for each V/J gene combination. c Clonality in the CD8+ T cell repertoires of HD (closed blue
circles, n= 12), SuS (closed cayenne squares, n= 14), and MS (closed red triangles up, n= 15) patients (left). Clonality in the total CD8+ T cell and CD8+
TEMRA repertoire of SuS (n= 6) patients (right). d Clonality of SuS patients with clinically active disease (closed cayenne squares, n= 6) or in clinical
remission (open cayenne squares, n= 8). e Quantification of the ten most prevalent clones in the CD8+ T cell repertoires of HD (closed blue circles, n=
12), SuS (closed cayenne squares, n= 14), and MS (closed red triangles up, n= 15) patients (left), as well as in the total CD8+ T cell and CD8+ TEMRA
repertoire of SuS (closed cayenne squares, n= 6) patients (right). f Graph representing the proportion of viral, public, SuS-specific public, and SuS-specific
private clones in the ten most prevalent clones in the total CD8+ T cell (left) and TEMRA (right) repertoire of SuS patients. Statistical analysis was
performed using Kruskal–Wallis test with Dunn’s post-test (a, c, e left graph) or unpaired Student’s t test (c right graph; d, e right graph), respectively. Error
bars indicate the mean ± s.d.; p values: *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. Source data are provided as a Source Data file.
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Encouraged by these findings, we treated off-label four SuS
patients with a progressive relapsing disease course and who did
not respond to prior immune therapies. Notably, the four patients
treated with natalizumab seemed to have reduced relapse rate and
disease progression (Fig. 7d, e), as far as the limited pretreatment
time windows in two of the patients permit the conclusion.
Calculation and visualization were performed in analogy to Cree
et al.47. Moreover, in two instances natalizumab discontinuation
was followed by relapses (Fig. 7d). As an example, a reduction in
CNS inflammation was demonstrated on magnetic resonance
imaging (MRI) with fewer SuS characteristic “snowball-like”
lesions48 in the corpus callosum of a SuS patient, 15 months after
initiating natalizumab treatment (Fig. 7f). Despite all caution
related to the off-label use of natalizumab in only four patients,
this suggests that VLA-4 blockade attenuates pathogenic immune
cell trafficking but, given the relapses upon cessation, probably
does not silence the underlying immune process.
Thus, using anti-α4 integrin as a therapeutic approach
corroborates our hypothesis that CD8+ T cells promote the
development of an endotheliopathy in SuS and are a potential
therapeutic target for such pathology.
Discussion
Our study suggests that SuS is a CTL-driven endotheliopathy
against unidentified antigen(s). In-depth functional immune
phenotyping and TCR profiling of blood and CSF lymphocytes
from patients with SuS revealed CTLs, specifically terminally
differentiated CD8+ TEMRA cells, to be putative actors in its
pathogenesis. The pathology of SuS brain lesions provides strong
evidence for a cytolytic endotheliopathy, in which CD8+ T cells
recognize an unknown antigen on ECs, resulting in endothelial
damage, small ischemic foci, and microhemorrhages. Using a
reverse translational approach, we directly tested for causation
in vivo between EC-targeting CTLs and the main neuropatho-
logical features of SuS in a mouse model. A similar pathology
could be induced experimentally in this mouse model, in which
CTLs target a neo-antigen expressed in ECs of the brain, retina,
and inner ear, using a promoter expressed in ECs exhibiting tight
junctions38–40,49. However, the phenotypes may not be exclu-
sively linked to T cell engagement of BBB ECs as the Slco1c1
promoter can be active in choroid plexus and some CNS-resident
cells39. Disease amelioration was achieved in the mouse model by
blocking adhesion and trafficking of CTLs using an anti-α4
integrin mAb. Finally, we translated these findings back to the
clinic by treating four SuS patients with natalizumab. Partial
attenuation of inflammatory activity in these patients further
corroborates the role of T cell/EC contact in SuS pathogenesis.
We investigated the pathophysiological processes underlying
SuS to gain further insight into immune cell/EC interactions
resulting in BBB dysfunction. A recent study revealed that murine
MOG-specific CD4+ T cells increase the BBB permeability in an
IFN-γ, GrB, and contact-dependent manner indicating a causa-
tive role of T cells in BBB dysfunction50. However, the particular
role of CD8+ T cells in brain endothelium damage remains
mostly unknown. Collectively, although the contribution of
CD4+ T cells remains to be investigated, our results argue that
SuS is a CD8+ T cell-driven microvascular endotheliopathy
associated with neuro-inflammation (Fig. 8). It is therefore
tempting to speculate that circulating, activated, clonally expan-
ded CD8+ TEMRA cells accumulate in CNS microvessels, where
they are involved in the induction of EC apoptosis. Endothelial
injury may result in vascular leakage and lead to the formation of
small ischemic lesions predominantly in the corpus callosum,
cerebellum, retina, and inner ear.T
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CD8+ T cells participate in the endotheliopathy that is a
hallmark of experimental cerebral malaria51,52 suggesting that
CD8+ T cell-mediated induction of BBB leakage may be a general
mechanism also occurring in other neuro-infectious (e.g., viral,
toxoplasmosis)53,54 or putative autoimmune neuro-inflammatory
diseases (e.g., Rasmussen encephalitis55). While our findings
point toward key mediators of cytotoxic vascular breakdown,
recent work in an animal model of cerebral malaria elegantly
demonstrated that the vascular breakdown associated with
alterations in tight junction protein expression is predominantly
mediated by IFN-γ52. Furthermore, alterations in tight junctions
were also observed in a natural feline model for LGI1 encephalitis
where the ECs stay intact, but tight junctions are lost. While
many studies focus on the mechanisms of transmigration and
trafficking into the brain, ECs have rarely been considered as a
target of antigen-specific immune recognition or BBB breakdown
a consequence of an endothelial-directed immune attack in
neuro-inflammation. Of note, while apoptosis of brain ECs was
consistent and marked in SuS, it was mostly absent in MS patients
indicating that in SuS CD8+ T cells attack the endothelium,
whereas in MS they mainly transmigrate across the BBB. Our
histological data clearly showed attachment of CTLs to brain ECs
raising the question how CD8+ T cells mediate attachment to the
microvessels despite high shear force. Collectively, our data argue
for a plausible scenario in which VLA4/VCAM-1 binding enables
physical interaction between CD8+ T cells and brain ECs. In turn,
this interaction facilitates TCR recognition of MHC:peptide
complexes on the luminal side of ECs. The subsequent release of
IFN-γ may further enhance VCAM-1 and MHC class-I expres-
sion on ECs, facilitating the cognate interactions between antigen-
specific CD8+ T cells and ECs. Under shear flow conditions,
primed T cells have been shown to adhere stronger to brain ECs
than their naive counterparts56. However, further studies are
warranted to identify the molecular mechanisms used by CD8+
T cells in different neuro-inflammatory diseases to create BBB
leakage and promote brain pathology.
Our study mainly focused on the pathophysiological role of
CD8+ T cells on ECs in the context of SuS. As previously shown9,
and confirmed here, CD8+ T cells (and other immune cells)
infiltrate the CNS parenchyma of SuS patients, where they cause
microhemorrhages and neural tissue destruction. Activation,
clonal expansion, and differentiation into CD8+ TEMRA
cells20,57,58 indicate priming of CD8+ T cells with cognate antigen
(s) presented on MHC class-I molecules as a crucial pathogenic
step in SuS. T cell responses to a single antigen can be orche-
strated by different T cells exhibiting specificities to distinct
antigenic epitopes resulting in multiple disease-specific clones
within the TCR repertoire. T cell responses to specific antigens
a b
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Fig. 3 CTLs are more prevalent in the periphery of SuS patients. a Representative examples (top) and quantification (bottom) of granzyme B (GrB; left)
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regulatory T cells. Left: Graphs representing the degree of suppression of proliferation of HD CD8+ T cells upon co-culture with titrated numbers of Treg
from HD (closed blue circles) and SuS (closed cayenne squares) (n= 3). Right: Graphs representing the degree of suppression of HD (closed blue circles,
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are likely to involve clones that are public and shared by indivi-
duals with response to the same MHC:peptide complex25. A
recent study by Zhao et al. suggested that autoimmunity is mainly
driven by public clones59. Here we found SuS-specific public
clones that were shared among at least two SuS patients and
absent in both published common viral and clones expanded in
other diseases26–29. These findings further support the idea that
an antigen-dependent process, with similar antigen(s) across
different individuals suffering from the disease, is a prerequisite
for the disease. This hypothesis was further strengthened by our
observation that clonality of CD8+ T cells is also associated with
the disease course, similar to another potentially CD8+ T cell-
driven disease, Rasmussen encephalitis24. Memory subsets such
as CD8+ TEM60 and CD8+ TEMRA cells are known to comprise
the majority of antigen-primed CD8+ T cells, and accordingly, we
observed the highest degree of clonal expansion within the CD8+
TEMRA subset.
Further support for the possibility of public clones
perpetuating the disease comes from HLA analysis. Except for
one SuS patient who was homozygous for HLA-C*04, all SuS
patients expressed HLA-C*06 and/or HLA-C*07. Comparing the
peptide-binding motifs of these HLA-C allotypes revealed that the
binding motif of HLA-C*06:02 and HLA-C*07:02 are almost
identical. The homology of the HLA–peptide binding for these
two allotypes has been recently proven in a study clustering
distinct HLA-C allotypes according to predictive binding
motifs32. Cluster analysis indicated that HLA-C*06:02 and HLA-
C*07:02 bind the cognate peptide and cluster together in close
proximity to HLA-C*0432. Since we identified identical clones in 3
out of 12 patients who share HLA-C*07, it is tempting to spec-
ulate that these disease-specific public clones might recognize the
same antigen/HLA complex. Thus a similar genetic background
might evoke similar immunological mechanisms that shape the
CD8+ T cell-mediated autoimmunity. However, most of the SuS-
specific clones found in the CD8+ TEMRA repertoire were private
to individual SuS patients. Although this might hint toward
recognition of different antigens, it does not exclude that some of
them might also recognize similar antigens, because HLA-peptide
recognition by TCRs61 is highly degenerate, i.e., a given
HLA–peptide complex can be recognized by structurally diverse
TCRs. Furthermore, such clones may have developed owing to
epitope spreading in the course of the disease.
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Why would brain ECs act as a target for CD8+ T cell recog-
nition? There are different possibilities, although the nature of the
targeted antigen(s) is currently unknown. One hypothesis is virus
infection that results in the presentation of viral-derived peptides
on the endothelium of the affected organs and/or in upregulation
of HLA class-I expression presenting viral or self-peptides on
ECs. For example, a study by Petty et al. showed that patients
with retinocochleocerebral vasculopathy had a previous cytome-
galovirus (CMV) infection. This raises the question as to how
CD8+ T cells of SuS patients circumvent common resistance
mechanism of ECs toward CTL-mediated attack. A recent study
has shown that upregulation of programmed death ligand 1 on
ECs during systemic lymphocytic choriomeningitis mammar-
enavirus infection inhibits killing of infected ECs by virus-specific
CTLs62, and further studies are warranted to reveal the under-
lying mechanisms resulting in an antigen-specific lysis despite
these protective mechanisms, as shown in the current study.
Although CMV-derived antigens also induce CD8+ TEMRA dif-
ferentiation63,64, the absence of CMV-related clones (except for
one patient) among the top ten expanded clones of the CD8+
TEMRA repertoire of SuS patients strongly suggests that CMV, a
dominant member of the herpes virus family, is not the driving
force in this disease. This was further corroborated by our finding
that we could not find CMV infection of ECs in our SuS cases. An
alternative hypothesis is a CD8+ T cell-mediated autoimmune
reaction against endothelium-specific antigen(s). The existence of
SuS-specific public and private clones that were absent in 1052
published viral clones favors the hypothesis of presentation of
endogenous peptides by ECs. Additional experiments, e.g., using
endothelium-derived antigen libraries, might provide further
support for this hypothesis.
Our mouse model clearly demonstrated that ECs are primarily
attacked and killed in an antigen-specific processes mediated by
CTLs, when the respective antigen is presented in the context of
MHC class-I molecules on the endothelium. Whether disease-
specific antigen expression on microvascular ECs of SuS patients
also induces killing by CD8+ T cells needs to be further eluci-
dated. However, existence of AECA in some SuS patients12,13,65
points in this direction. Influence of CD8 T cells might be tran-
sient, leading to functional disturbance of the BBB, or permanent,
leading to destruction of EC, as demonstrated here.
Finally, as a proof of principle, treatment of SuS patients with
natalizumab, a humanized mAb directed toward the α4 integrin
(CD49d) that prevents binding of VLA-4-expressing lymphocytes
to VCAM-1 expressed on inflamed ECs44,46,66, was used to
demonstrate the potential impact of a non-antigen-specific dis-
placement of CD8+ T cells from microvessels of the affected
organs as means to ameliorate the disease, thereby indirectly
corroborating our hypothesis of the direct involvement of these
T cells in endothelial injury. Although the number of treated
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patients is too limited to draw firm conclusions, and despite one
previously reported case of putative SuS not benefiting from this
therapy67, treatment with natalizumab along with other therapy
was associated with a reduced clinical and paraclinical activity
and fewer relapses in the four treated patients. Relapse activity
occurring after discontinuation of the natalizumab treatment in
two patients not only supports the putatively beneficial role of
this drug in SuS but also suggests that it does not resolve the
underlying condition. Thus natalizumab may offer a more tar-
geted and effective treatment regimen in addition to the current
treatment recommendations68 and even more generally for dis-
eases where CD8+ T cell-mediated degeneration can be con-
sidered a key element (e.g., Rasmussen encephalitis69).
Depending on the disease, treatment with efalizumab (a huma-
nized anti-LFA-1 antibody) that also prevents binding of lym-
phocytes to the endothelium may be an alternative to
natalizumab. Along these lines, a recent study demonstrated that
anti-LFA1 antibody treatment resulted in disease amelioration in
the animal model of experimental cerebral malaria by a
mechanism displacing CD8+ T cells from cerebrovascular ECs52.
Nevertheless, further studies are required to elucidate which of
these treatments is the most efficacious. For that purpose, the
SuS-like mouse model developed in this study will be valuable.
Our study highlights a potential fruitful avenue of research
focusing on the role of CD8+ T cells recognizing and interacting
with brain endothelium. Given that this mechanism is relevant to
several neuroinflammatory and neuroinfectious diseases, further
characterization of the nature of the target antigen(s), the reac-
tivity patterns of ECs under physiological and pathological con-
ditions, and approaches to interfere with this key pathogenic step,
potentially using this animal model, are important next steps to
follow.
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Methods
Patients and controls. Forty patients with definite and two patients with probable
SuS according to the recently defined diagnostic criteria were included in this
study6. Demographic data of all the patients are summarized in Supplementary
Table 1. Twenty of the 42 SuS patients were active at the time point of withdrawal.
While 16 of 42 patients were therapy naive, 24 of the 42 patients were on corti-
costeroids (5 of these patients also received intravenous immunoglobulin (IVIg)),
and 2 of 42 patients were on IVIg at the time point of withdrawal. Peripheral blood
mononuclear cells (PBMCs) from 262 treatment-naive patients with a stable
(n= 93) or active (n= 189) relapsing–remitting MS fulfilling the revised McDo-
nald criteria70 and 77 age-and sex-matched healthy donors served as controls.
Seventy-six individuals with somatoform disease also served as non-inflammatory
controls for CSF analysis. The latter group included patients who were admitted to
the hospital because of physical symptoms (i.e., tingling paresthesia) suggesting,
e.g., an inflammatory CNS disease, but all clinical, imaging, electrophysiology, and
laboratory evaluations were unremarkable. All patients included in this non-
inflammatory control group fulfilled the following laboratory criteria defining a
non-inflammatory CSF: <5 cells µl−1, <500 mgml−1 CSF protein, <2 mM lactate,
no disruption of the blood/CSF barrier (defined by the serum/CSF albumin quo-
tient), no intrathecal IgG synthesis (defined by the oligoclonal band pattern), and
no intrathecal IgG, IgA, and IgM synthesis (defined by the Reiber’ criteria). Six
additional MS patients and six patients with no neurological disorders served as
controls for the histological staining. All studies and clinical investigations were
conducted according to the Declaration of Helsinki and approved by the ethic
committee of the University of Münster: registration nos. 2010-262-f-S, 2011-665-
f-S, 2014-068-f-S, 2012-407-f-S; and the ethics committee of the Medical University
of Vienna: registration nos. 1206/2013 and 1123/2015. All patients provided
written formal consent before participating in the study. Lumbar puncture and
CNS biopsy were only performed for diagnostic reasons.
As there are no approved treatment options for SuS, treatment with
natalizumab, a licensed humanized mAb approved for the therapy of active MS,
was used off-label in four patients who did not respond to other immune therapies.
All patients planned to receive natalizumab were thoroughly informed about the
off-label nature of this approach and their consent was documented in the patients’
report by the treating physician.
Mouse strains. The double transgenic EC-HA+ mice, expressing HA in CNS
microvessel ECs, were generated by crossing the Rosa26tm(HA)1Lib with Slco1c1-
CreERT239,71 mice, as Slco1c1-CreERT2 mice allow restricted expression in brain
ECs. EC-HA+ mice and single transgenic littermate control mice, named EC-HA−,
were treated for 5 consecutive days with tamoxifen intraperitoneally (i.p.; 1 mg per
mouse per day). The CL4-TCR mice72 were the source of the HA-specific CD8+
T cells. Both the recipient and the donor mice were bred on the same [BALB/c ×
C57BL/6]F1 background. As recipient mice, for each experiment, we used litters
from the first generation of the crossing between Rosa26tm(HA)1Lib BALB/c mice
and Slco1c1-CreERT2 C57BL/6 mice. As donor mice, we used CL4-TCR transgenic
progeny from the cross of CL4-TCR transgenic mice (backcrossed for >10 times on
the BALB/c background) with CD45.1+ C57BL/6 mice. Mice were kept in
specific pathogen-free conditions and used in accordance with the European
Union guidelines following approval of the local ethics committee (16-U1043
RL/CM-653).
MRI and CSF routine diagnostics. MRI was performed on 1.5 or 3 Tesla scanners.
Diffusion-weighted imaging with calculation of apparent diffusion coefficient map,
axial and coronal T1-weighted spin-echo before and after application of gadoli-
nium, coronal and sagittal fluid-attenuated inversion recovery, axial fast T2-
weighted field-echo, and axial turbo T2-weighted spin-echo sequences and diffu-
sion tensor imaging were performed in the patients.
CSF cells were counted using a Fuchs–Rosenthal chamber. Total protein levels,
integrity of the blood/CSF barrier, and intrathecal Ig synthesis were analyzed using
a nephelometer (Siemens) according to the guidelines by the manufacturer. The
oligoclonal band pattern was analyzed by electrophoresis and subsequent silver
staining (GE Healthcare).
Cells and cell culture. Human blood was collected in EDTA-containing tubes
(K2E Vacutainer, BD) and processed within 24 h. PBMCs were isolated by density
gradient centrifugation using lymphocyte separation medium (PAA Laboratories).
Immune cells were cultured in complete medium (RPMI 1640 medium
supplemented with 10% fetal bovine serum, L-glutamine; all Hyclone) for
degranulation assays or in X-Vivo15 (Lonza) for suppression assays. PBMCs for
use in TCR Vβ spectratyping and TCR Vβ sequencing were cryopreserved in liquid
nitrogen using CTLCABC-cryo freezing media (Immunospot). Frozen PBMCs
were thawed by placing vials with frozen cells into a pre-warmed water bath (37 °C)
for 8 min. Subsequently, the cell suspension was transferred into a 50-ml conical
tube and slowly mixed with pre-warmed RPMI medium supplemented with 10%
fetal calf serum (FCS). The cell suspension was centrifuged at 300 × g at room
temperature and resuspended in pre-warmed cell culture medium until further
processing.
Primary HBMECs (ScienCell) were cultured in speed-coat (Pelobiotech) treated
cell-culture flasks in EC medium supplemented with FCS, penicillin/streptomycin,
and EC growth supplement (ScienCell).
Mouse Mastocytoma cell line P815 (ATCC) was maintained in Iscove’s
Modified Dulbecco’s Medium/10% FCS.
Table 2 Neuropathological evaluation of SuS patients and Slco1c1-HA/EC-HA mice.
SuS Slco1c1-HA/EC-HA mice
Frequent location of lesions
Leptomeningesa,b,c Leptomeninges
ND Choroid plexus
Snow ball lesions in corpus callosuma,b,c Corpus callosum
Subcortexa,b,c Subcortex
Cerebelluma,b,c Cerebellum
ND Spinal cord
Retinab,c Retina
Inner earb Inner ear
Target cells Brain ECsa,b,c Brain ECs
Neuropathological changes
Binding of CTLs to luminal side of BVs, invasion into vessel wallsa, moderate
parenchymal infiltration of CD8+ T cells, rare number of CD20 B cells, and
the absence of plasma cellsa,b,c
Binding of CTLs to luminal side of BVs, parenchymal
infiltration of CD8+ T cells
Occlusion of BVs, swollen ECs, thickened vessel wallsb,c, apoptosis of ECsa,
focal disruption of the BBB, microhemorrhages/microinfarctsa,b,c
Occlusion of BVs, apoptosis of ECs, focal disruption of
the BBB, microhemorrhages/microinfarcts
Ischemic lesions with local loss of neurons, astrocytes, and
oligodendrocytesa,c
Ischemic lesions with local loss of neurons, astrocytes,
and oligodendrocytes
Immune mechanism
Targeting of ECs by CD8+ T cells against unknown EC antigen(s)a Targeting of ECs by MHC-restricted HA-specific CD8+
T cells
No detection of deposition of Ig and complementa,c No detection of deposition of Ig and complement
Table comparing the neuropathological findings between SuS patients and the EC-HA mouse model
BBB blood–brain barrier, BV blood vessel, CTL cytotoxic T cell, EC endothelial cell, Ig immunoglobulin, ND not detected
aThis manuscript
bDörr et al., based on MRI findings7
cAgamanolis et al. and Hardy et al.: based on neuropathological evaluation9,16
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Purification and isolation of cells. For TCR spectratyping, sequencing, and
physiological flow assays, CD8+ T cells and CD4+ T cells were purified from
cryopreserved PBMCs using the CD8+ and CD4+ T cell-negative isolation kits
(MACS® magnetic cell separation, Miltenyi Biotech).
For the CDR3-Vβ TCR sequencing of CD8+ TEMRA cells, cryopreserved PBMCs
were thawed and CD8+ TEMRA cells were enriched using fluorescence-activated cell
sorting (BD FACSAriaTM III). The purity of the sorted CD4+ T cells, CD8+ T cells,
and CD8+ TEMRA cells was ≥90%.
For T cell-suppression assays, Treg were isolated by positive selection of CD25+
cells (Miltenyi Biotech) followed by the depletion of CD8+ (2 beads per cell),
CD14+ (1 bead per cell), and CD19+ (2 beads per cell) cells using dynabeads
(Invitrogen). The remaining cells are enriched for CD4+ Treg cells with >80%
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d Clinical episodes (closed black diamonds) of 4 SuS patients receiving treatments with 300mg natalizumab monthly (cayenne line), oral prednisolone,
tapered from 1 mg/kg body weight (yellow line), pulses of methylprednisolone, 1 g for 5 days (closed yellow diamonds), monthly IVIg 0.4 mg/kg body
weight for 5 days (open white line), or other treatments, including cyclophosphamide, plasma exchange, mycophenolate mofetil, and azathioprine (blue
line). *Patient 23 is still under treatment with natalizumab, while patients 25, 12, and 22 are not. e Bar graph representing the disease score of the four SuS
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purity. Effector T (Teff) cells were purified from PBMCs by depletion of CD25+
Treg cells using CD25 dynabeads (Invitrogen).
For purification of mouse mononuclear cells, mice were anesthetized with
ketamine (100 mg kg−1) and xylazine (10 mg kg−1) and perfused intracardially
with phosphate-buffered saline (PBS). Spleen was collected and dissociated, and red
blood cells were lysed. Brains were removed and homogenized, followed by
digestion with collagenase D (1 mgml−1), DNase I (10 mgml−1), and TLCK
(0.02 mgml−1), and CNS-infiltrating mononuclear cells were then isolated using
Percoll density separation, for 30–40 min at 37 °C. After a washing step,
mononuclear cells were collected following a Percoll gradient separation. To
generate HA-specific CTLs, 20 × 106 purified naive CD8+ T cells from CD45.1+
CL4-TCR (BALB/c × C57BL/6)F1 mice were stimulated with 100 × 106 irradiated
syngenic splenocytes in Dulbecco’s modified Eagle’s medium supplemented with
10% FCS containing 1 µg ml−1 HA512–520 peptide, 1 ng ml−1 interleukin (IL)-2,
and 20 ng ml−1 IL-12. On day 5, cells were collected by Ficoll density separation
and 0.3 × 107 or 3 × 107 living CTLs were injected IV in recipient mice.
Flow cytometry and antibodies. Flow cytometry of whole blood and CSF cells
was performed by adding 1ml VersaLyse buffer (Beckman Coulter) to 100 µl
whole blood or CSF cells. Following 10-min incubation at room temperature, 1ml
PBS/0.5% bovine serum albumin (BSA)/2mM EDTA is added and cells are cen-
trifuged for 4 min at 290 × g. Supernatant was discarded and cells were washed
once with 3ml PBS/0.5% BSA/2mM EDTA. Afterwards cells were stained with
the respective fluorochrome-conjugated mAbs (listed in Supplementary Table 5)
for 30min at room temperature. Following one wash step with 1ml PBS/0.5% BSA/2
mM EDTA, cells were resuspended in 200 µl buffer and 20 µl flow count fluoro-
spheres (Beckman Coulter) were added. Samples were acquired on a Navios flow
cytometer (Beckman Coulter). Resulting data were analyzed with Kaluza 1.5a
(Beckman Coulter).
For cell-surface staining of PBMCs, cells were stained with fluorochrome-
conjugated mAbs (listed in Supplementary Table 5) in PBS/0.5% BSA/2 mM EDTA
at 4 °C for 30 min. For the identification of GrB and perforin expression, surface-
labeled cells were permeabilized with fixation/permeabilization solutions (BD
Cytofix/Cytoperm™) followed by intracellular staining with fluorescence-labeled
mAbs for the proteins (Supplementary Table 5). Intra-nuclear staining for Foxp3
was performed using the Foxp3/Transcription Factor Staining Buffer Set
(eBioscience) according to the manufacturer’s instructions. Naive/memory T cells
were assigned based on CD45RA and CD62L expression for ex vivo analyses.
Owing to shedding of CD62L upon thawing, CD27/CD45RA was used to identify
naive/memory T cells for thawed cells used for detailed phenotyping and sorting of
TEMRA cells. Cell proliferation was tracked by labeling PBMCs with eFluor670
(eBioscience) according to the manufacturer’s protocol. Labeled human samples
were measured on a Gallios flow cytometer (Beckmann Coulter) and analyzed
using Kaluza 1.5a (Beckman Coulter).
For immune cells from EC-HA+ and EC-HA− mice, surface staining was
performed with directly labeled antibodies (Supplementary Table 3) in flow
cytometric buffer. To assess degranulation and intracellular cytokine production,
cells were cultured for 4 h in the presence of 5 μg ml−1 allophycocyanin-labeled
anti-CD107a antibody and Golgi Stop (BD). Cells were stimulated in vitro with
phorbol myristate acetate (1 μg ml−1, Sigma), ionomycin (1 μg ml−1, Sigma), and
Golgi Plug (BD) for 4 h, followed by intracellular staining for IFN-γ and TNF-α
using BD Cytofix/Cytoperm. Mouse data were collected on a LSRII Fortessa flow
cytometer (BD) and analyzed with the FlowJo software (Tree Star).
(Quantitative) histopathology and immunofluorescent staining. Mice were
perfused with PBS followed by 4% paraformaldehyde. Tissues were removed and
embedded in paraffin.
Immunohistochemical and immunofluorescence staining was performed on
3–5-µm-thick mouse or human serial sections using the primary antibodies
indicated in Supplementary Table 5. Before incubation with primary antibodies,
antigen retrieval was performed by heating the sections for 60 min in EDTA
(0.05 M) in tris(hydroxymethyl)aminomethane (Tris) buffer (0.01 M, pH 8.5) or
citrate buffer (0.01 M, pH 6) in a household food steamer device for all antibodies
except for anti-C9 neo and anti-Ig, in which case antigen retrieval was performed
by incubating the tissue for 15 min in proteinase (bacterial proteinase Type XXIV,
#SLBQ7212V, Sigma Life Science) at 37 °C. For confocal fluorescent double
labeling or triple labeling with primary antibodies from different species, primary
antibodies were applied simultaneously at 4 °C overnight. After washing with
DAKO washing buffer (DakoCytomation, Glostrup, Denmark), Cy2-, Cy3-, or
Cy5-conjugated secondary antibodies were applied simultaneously for 1 h at room
temperature. For fluorescence triple labeling with two antibodies from the same
species, we label the first primary antibody (i.e., mouse-anti-CD31) with a
biotinylated secondary antibody and follow-up by tyramide-based amplification of
the biotin signal. We then again boil the sections for 30 min in EDTA buffer to
completely strip (deactivate) this primary antibody. After this, we incubated with
Cy3-conjugated avidin to retrieve the biotin signal, followed by performing a
second round of staining with a mixture of primary antibodies from different
species (i.e., rabbit-anti-CD8 and mouse-anti-GrB). The staining is finished by
Cy2- and Cy5-conjugated secondary antibodies. Fluorescent preparations were
embedded and examined using a confocal laser scan microscope (Leica SP5, Leica
Mannheim, Germany) equipped with lasers for 504, 488, 543, and 633 nm
excitation. Scanning for Cy2 (488 nm), Cy3 (543 nm), and Cy5 (633 nm) was
performed sequentially to rule out fluorescence bleed through. Quantification of
immunohistochemistry data was performed by counting density of CD3+ cells in
various regions of the brain. In each region, the number of T cells in an area of
2 mm2 were counted by using a morphometric grid. Optical density of Ig leakage of
total brain sections or individual cortical or hippocampal regions was analyzed
using Image J. Quantification of immune cells of human immunohistochemistry
data was performed by counting cells using a morphometric grid. Owing to the
different sizes of the specimens, areas analyzed ranged from 5 to 48 mm2 (on
average 14 mm2). Quantification of apoptosis of ECs was performed by analysis of
nuclear condensation of CD34+ ECs. For this, SuS, MS lesions, and control
sections were investigated at ×400 magnification, counting a minimum of 50 cells
(in the smallest specimen) to a maximum of 250 cells. The same method was used
for analysis of apoptosis in the cerebelli of mice. Here on average 120 ECs were
counted. Attachment of CD8+ CTLs to blood vessels was performed on SuS and
MS sections double labeled with CD8 and CD34. Parenchymal CD8+ CTLs and
CD8+ CTLs attached to the luminal or perivascular side of CD34 stained ECs were
counted and the percentage of attachment was calculated. On average, 99 CTLs in
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Susac and 194 cells in MS were counted. Fluorescent preparations were examined
using a confocal laser scanning microscope (Leica SP5).
RNA isolation and reverse transcriptase-PCR. For TCR profiling, RNA was
isolated from human CD8+ T cells, CD4+ T cells, and CD8+ TEMRA cells using the
RNAeasyTM Kit (Qiagen) according to the manufacturer’s instructions. cDNA was
prepared from 0.5 to 1 µg isolated RNA by reverse transcription using reagents
including reverse transcriptase, dNTPs, and random hexamers (Life Technologies).
To assess HA gene expression in mice, total RNA was extracted from mouse tissue
with the RNeasy Mini-kit or RNeasy Micro-kit plus (Qiagen), followed by reverse
transcription using RevertAidH Minus Revert Transcriptase (ThermoFisher).
The cDNA prepared from mouse tissue was used as a template for quantitative
PCR using SYBR Green I master mix (Roche) and assessed in a thermocycler
(LightCycler 480; Roche). mRNA expression was normalized to that of HPRT
mRNA. Specific primers were used to amplify HA (forward, 5′-AAACTCTTCG
CGGTCTTTCCA-3′; reverse, 5′-GATAAGGTAGCTTGGGCTGC-3′), and HPRT
(forward, 5′TGGTTAAGCAGTACAGCCCCAA-3′; reverse, 5′-AGGTCCTTTTCA
CCAGCAAGCT).
TCR spectratyping. Spectratyping of the CDR3 sequences of TCR-Vβ-chains of
CD4+ and CD8+ T cell subsets was performed by multiplex PCR using 24 Vβ
forward primers and Cβ reverse primers “SpTy-b-out” and Cβ-R (provided by
Metabion, Martinsried, Germany)73,74. Data analysis of the spectratypes was per-
formed using the GeneMarker software (SoftGenetics, State College, PA, USA).
Complexity score was calculated based on the number of peaks across all
24 spectratypes per individual. A lower complexity score is indicative of a more
perturbed repertoire. Fragment length distribution classification was determined
based on the number of observed peaks and the area under the curve for each peak
in a spectratype. Gaussian distributed spectratypes were considered “normal”;
“shifted” spectratypes displayed all peaks with shifted maxima, “skewed” spec-
tratypes show reduced peak numbers and non-Gaussian distributions, and spec-
tratypes with only 1–2 peaks that were twice the height of comparable peaks of a
normally distributed spectratype were considered “oligoclonal.”
High-throughput TCR sequencing. TCRs of CD8+ and CD4+ T cells isolated
from the blood of HD, SuS, and MS patients were profiled with high-throughput
TCR sequencing. The ImmunoSEQ assay (Adaptive Biotechnologies), a multiplex
PCR system, was used to amplify 54 expressed Vβ and 13 Jβ segments. The
resulting amplicons span and sufficiently identify the VDJ region of each unique
CDR3β22. PCR bias was corrected using a baseline platform developed from a suite
of synthetic templates to optimize primer concentrations and for computational
corrections. The amplicons were deep sequenced using the Illumina HiSeq plat-
form. The raw reads were annotated into V, D, and J gene definitions according to
the IMGT (ImmunoGeneTics) database (http://www.imgt.org). The TCR reads
were pre-processed and data were analyzed with the ImmunoSEQ Analyzer soft-
ware. Productive sequences excluding those that were out of frame or have a stop
codon were considered for all analyses. Perturbations in the repertoire were
computed as clonality. Clonality is based on Shannonʼs entropy, wherein clonality
is equivalent to 1− normalized entropy (normalized entropy= entropy/log2
(productive unique)). Clonality ranges from 0 to 1 where a value closer to 1
represents a repertoire dominated by select clones. Identification of private/
public clones was performed as previously published24. SuS-specific clones were
defined as clones absent in 27 control HD (n= 12) and MS cohorts (n= 15),
1052 published viral clones including 956 CMV clones, and other published
sequences curated in the ImmuneACCESS database. Private clones were defined as
those clones exclusively found in one individual while public clones are non-
exclusive to the individual.
Degranulation assay. To assess the release of cytotoxic granules of CD8+ T cell in
response to polyclonal stimulation by anti-CD3-loaded on P815 cells75, PBMCs
were mixed in a 1:1 ratio with P815 target cells and incubated in the presence of
10 µl ml−1 Golgi plug (BD Bioscience), 0.0625 µg ml−1 anti-CD3 (Biolegend), and
0.25 µg ml−1 CD107a-AF488 antibody (Biolegend) for 3 h at 37 °C/5% CO2. Fol-
lowing incubation, cells were centrifuged at 300 × g for 10 min at room temperature
and stained for lineage-defining surface markers for 30 min at 4 °C. Following
washing, samples were acquired by flow cytometry. Degranulation of CD8+ T cells
was assessed as the percentage of CD107a+-expressing CD8+ T cells.
T cell-suppression assay. For T cell-suppression assays, 5 µM eFluor-670
(eBioscience) labeled Teff cells were cultured either alone or co-cultured with
titrated numbers of Tregs in 1:1 to 1:0.08 ratio. Therefore, Teff were isolated from
PBMCs by depletion of CD25-expressing cells using CD25 dynabeads (Invitrogen)
as described above. Teff cells were labeled with eFluor-670 according to the man-
ufacturer’s instructions. Teff cells were mixed with Treg isolated from independent
donors and were polyclonally stimulated with 0.5 µg ml−1 aCD3 (clone OKT3,
Biolegend) in X-Vivo15 medium (Lonza) for 4 days at 37 °C/5% CO2. Following
incubation, cells were stained with lineage-defining fluorochrome-conjugated
antibodies and acquired by flow cytometry. Suppression of Teff proliferation was
evaluated by tracking the dilution of eFluor-670 dye on CD4+ and CD8+ Teff cells
in cultures in comparison to cultures with and without Treg.
Physiological flow assay. Physiological flow assays were performed in flow
chambers (0.4 µm slides; IBIDI) with monolayers of HBMECs (Pelobiotech).
HBMECs were treated with TNF-α (500 U ml−1; R&D Systems) for 18 h. CD8+
T cells (3.5 × 105 cells per slide) isolated from thawed PBMCs of healthy donors or
SuS patients were perfused at a constant shear stress of 0.25 dyn cm−2 for 5 min. If
indicated, T cells were incubated with natalizumab (Tysabri, Biogen; 10 µg ml−1)
for 10 min. Videos (×20 magnification) were recorded using a BZ-9000 BioRevo
microscope (Keyence) and BZ II viewer software (Keyence). Adherent cells per
field of view were determined using ImageJ (NIH).
Transfer of HA-specific CTLs. On day 5 of differentiation of HA-specific CTLs,
cells were collected by Ficoll density separation and 0.3 × 107 or 3 × 107 CTLs were
adoptively transferred IV to EC-HA+ mice and EC-HA− littermate controls. Mice
were assessed daily for weight and neurological signs. The motor skill and per-
formance were assessed using a Rotarod device (Bioseb), with acceleration from 4
to 40 rpm over a 600-s period. First, the animals were trained before treatment to
reach steady performance. The 1-week training consisted of 2–3 trials of 10 min
each with rest of 5 min between the trials. During the investigation period (days
0–28), the amount of time spent on the drum was measured daily for each mouse.
100% represents the day-0 value.
Antibody treatment of mice. The anti-α4 integrin antibody (clone PS/2; BioXCell,
West Lebanon, NH, USA) or a control rat IgG2b was injected into EC-HA+ mice
(250 µg per mouse i.p.) at the indicated time points.
Natalizumab treatment of patients. The humanized anti-α4 integrin antibody
(natalizumab (TysabriTM), Biogen, Boston USA), which blocks VLA-4 from
interacting with VCAM-1, was infused monthly at a fixed 300 mg dose of natali-
zumab every 28 days.
Statistical analysis. Statistical analysis was performed using the GraphPad Prism
5.0 software. Data in figures are represented as means ± standard deviation (s.d.).
D’Agostino-Pearson omnibus normality test was performed to test for Gaussian
distribution. Statistical significance for normally distributed data was determined
using unpaired, two-tailed Student’s t tests, while Mann–Whitney test was used for
non-parametric data to compare means between two independent groups. For
comparison of more than two groups, one-way analysis of variance with Bonfer-
roni post-test (parametric) or Kruskal–Wallis with Dunn’s post-test (non-para-
metric) was applied. Paired Student’s t test or Wilcoxon matched test was used for
different treatments within the same patient group. Correlation analysis was per-
formed using linear regression. p Values of <0.05 were considered significant
and indicated in the corresponding figures (*p < 0.05; **p < 0.01; ***p < 0.001;
****p < 0.0001).
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
There is no restriction in the availability of materials described in the study. Source data
are provided as a Source Data file. TCR sequences have been deposited to the BioProject
database under the accession number PRJNA579190.
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